<DOC>
	<DOCNO>NCT00804245</DOCNO>
	<brief_summary>RATIONALE : New diagnostic procedure , C-11 choline PET-CT scan , may effective find cancer spread bone lymph node patient prostate cancer . PURPOSE : This clinical trial study well C-11 choline PET-CT scan work find metastasis patient newly diagnose high-risk prostate cancer .</brief_summary>
	<brief_title>C-11 Choline PET-CT Scan Finding Metastases Patients With Newly Diagnosed High-Risk Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine sensitivity specificity PET-CT scan use C-11 choline detect bone lymph node metastases patient newly diagnose high-risk adenocarcinoma prostate . Secondary - To perform semi-quantitative analysis tracer uptake use standard uptake value qualitative analysis use pure visual analysis . - To develop algorithm include routine use C-11 choline PET-CT scan staging patient prostate cancer high risk metastatic disease . - To determine whether presence C-11 choline PET-CT scan positivity patient predictive outcome , include biochemical relapse-free survival , time development clinically apparent metastasis , time local failure , overall survival . - To obtain tissue specimens patient correlative study evaluation . - To obtain information regard feasibility characteristic C-11 choline PET-CT scan androgen suppression . OUTLINE : Patients undergo CT scan abdomen pelvis IV contrast bone scan . Patients also undergo C-11 choline PET-CT scan* . In case positive scan , patient undergo needle biopsy . If biopsy negative metastatic disease biopsy positive metastatic disease drain lymph node region , patient receive radiotherapy hormonal ( antiandrogen ) therapy . If biopsy positive metastatic disease site , patient receive hormonal therapy alone . NOTE : *The first 10 patient enrol study positive PET-CT scan positive biopsy undergo second PET-CT scan 6 month initial PET-CT scan . Patients follow every 3 month 1 year every 6 month 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Choline</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate Prior negative prostate biopsy allow Highrisk disease , define one following : PSA ≥ 20 ng/mL Gleason score ≥ 8 Digital rectal examination reveal ≥ T2c disease ( tumor involve one half one lobe prostate ) Creatinine &lt; 2.0 mg/dL Able tolerate PET scan , CT scan , bone scan Able tolerate IV oral contrast Willing undergo biopsy positive finding PETCT scan , CT scan , bone scan Other cancer within past 5 year ( except nonmelanoma skin cancer ) No prior radiotherapy , hormonal therapy , surgery ( biopsy ) , cryotherapy prostate cancer Prior transurethral resection prostate allow</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>